These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23065477)

  • 1. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study.
    Coglianese EE; Larson MG; Vasan RS; Ho JE; Ghorbani A; McCabe EL; Cheng S; Fradley MG; Kretschman D; Gao W; O'Connor G; Wang TJ; Januzzi JL
    Clin Chem; 2012 Dec; 58(12):1673-81. PubMed ID: 23065477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble ST2 predicts elevated SBP in the community.
    Ho JE; Larson MG; Ghorbani A; Cheng S; Vasan RS; Wang TJ; Januzzi JL
    J Hypertens; 2013 Jul; 31(7):1431-6; discussion 1436. PubMed ID: 23615326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality.
    Hughes MF; Appelbaum S; Havulinna AS; Jagodzinski A; Zeller T; Kee F; Blankenberg S; Salomaa V;
    Heart; 2014 Nov; 100(21):1715-21. PubMed ID: 25080471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction.
    Pascual-Figal DA; Ordoñez-Llanos J; Tornel PL; Vázquez R; Puig T; Valdés M; Cinca J; de Luna AB; Bayes-Genis A;
    J Am Coll Cardiol; 2009 Dec; 54(23):2174-9. PubMed ID: 19942089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea.
    Shah RV; Chen-Tournoux AA; Picard MH; van Kimmenade RR; Januzzi JL
    Circ Heart Fail; 2009 Jul; 2(4):311-9. PubMed ID: 19808354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of reference intervals for soluble ST2 from a United States population.
    Lu J; Snider JV; Grenache DG
    Clin Chim Acta; 2010 Nov; 411(21-22):1825-6. PubMed ID: 20654603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure.
    Gaggin HK; Motiwala S; Bhardwaj A; Parks KA; Januzzi JL
    Circ Heart Fail; 2013 Nov; 6(6):1206-13. PubMed ID: 24114865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction.
    Weir RA; Miller AM; Murphy GE; Clements S; Steedman T; Connell JM; McInnes IB; Dargie HJ; McMurray JJ
    J Am Coll Cardiol; 2010 Jan; 55(3):243-50. PubMed ID: 20117403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure.
    Mueller T; Dieplinger B; Gegenhuber A; Poelz W; Pacher R; Haltmayer M
    Clin Chem; 2008 Apr; 54(4):752-6. PubMed ID: 18375488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective.
    Jenkins WS; Roger VL; Jaffe AS; Weston SA; AbouEzzeddine OF; Jiang R; Manemann SM; Enriquez-Sarano M
    Am J Med; 2017 Sep; 130(9):1112.e9-1112.e15. PubMed ID: 28344136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure.
    Broch K; Andreassen AK; Ueland T; Michelsen AE; Stueflotten W; Aukrust P; Aakhus S; Gullestad L
    Int J Cardiol; 2015 Jan; 179():378-84. PubMed ID: 25464491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial.
    Anand IS; Rector TS; Kuskowski M; Snider J; Cohn JN
    Circ Heart Fail; 2014 May; 7(3):418-26. PubMed ID: 24622243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction.
    Manzano-Fernández S; Mueller T; Pascual-Figal D; Truong QA; Januzzi JL
    Am J Cardiol; 2011 Jan; 107(2):259-67. PubMed ID: 21211603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; McKie PM; Dunlay SM; Stevens SR; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases.
    Mueller T; Leitner I; Egger M; Haltmayer M; Dieplinger B
    Clin Chim Acta; 2015 May; 445():155-60. PubMed ID: 25850080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure.
    Bayes-Genis A; Pascual-Figal D; Januzzi JL; Maisel A; Casas T; Valdés Chávarri M; Ordóñez-Llanos J
    Rev Esp Cardiol; 2010 Oct; 63(10):1171-8. PubMed ID: 20875357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension.
    Zheng YG; Yang T; He JG; Chen G; Liu ZH; Xiong CM; Gu Q; Ni XH; Zhao ZH
    Clin Cardiol; 2014 Jun; 37(6):365-70. PubMed ID: 25068163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-1 receptor-related protein ST2 and mitral valve repair outcome in patients with chronic degenerative mitral regurgitation.
    Galeone A; Lessana A; Mascolo E; Di Serio F; Marraudino N; Laborde F; Paparella D
    Thorac Cardiovasc Surg; 2014 Feb; 62(1):47-51. PubMed ID: 24065602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reference interval and the role of soluble suppression of tumorigenicity 2 (sST2) in subclinical cardiac dysfunction at health checkups.
    Nah EH; Cho S; Kim S; Cho HI
    J Clin Lab Anal; 2020 Nov; 34(11):e23461. PubMed ID: 32638437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal changes of soluble ST2 after cardiovascular interventions.
    Willems S; Sels JW; Flier S; Versteeg D; Buhre WF; de Kleijn DP; Hoefer IE; Pasterkamp G
    Eur J Clin Invest; 2013 Feb; 43(2):113-20. PubMed ID: 23215810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.